Roche and Vividion discovered and developed the therapy through a 2020 global partnership and licence agreement.

ISM2196 is a novel, potent WRN inhibitor, designed with the assistance of Alchemistry, one of the latest modules of Chemistry 42. Disclaimer: AAAS and EurekAlert! are not responsible for the ...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently ...

which indicates WRN is a synthetic lethal target for MSI-H tumors. MSI-H condition is observed in more than 20 different types of cancers, especially in colorectal cancer, endometrial cancer ...

Vividion Therapeutics secures worldwide rights to develop & commercialize clinical-stage WRN covalent inhibitor, VVD-214: San Diego, California Friday, June 6, 2025, 11:00 Hrs [IS ...

Inhibition of WRN activity has the potential to induce synthetic lethality in MSI-high (MSI-H) tumors. Using a structure-based drug design approach, Nimbus developed highly potent and selective ...

Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high ...

WRN program, in lead optimization, (c) ONCO Prime platform, highlighting novel target discovery in synthetic lethality and (d) RVU120, with an update from the solid tumor study - AMNYS-51.

Ryvu PRMT5 inhibitors show potential best-in-class profiles, including a strong antiproliferative effect on MTAP-deleted cell lines and a good safety window versus MTAP WT cells.Ryvu's WRN ...